nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—TACR1—nerve—acquired immunodeficiency syndrome	0.055	0.237	CbGeAlD
Vapreotide—SSTR2—digestive system—acquired immunodeficiency syndrome	0.0241	0.104	CbGeAlD
Vapreotide—SSTR5—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0221	0.0288	CbGpPWpGaD
Vapreotide—SSTR2—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0204	0.0266	CbGpPWpGaD
Vapreotide—SSTR2—nervous system—acquired immunodeficiency syndrome	0.0186	0.0802	CbGeAlD
Vapreotide—SSTR2—central nervous system—acquired immunodeficiency syndrome	0.0179	0.0773	CbGeAlD
Vapreotide—SSTR2—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.0173	0.0226	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0172	0.0224	CbGpPWpGaD
Vapreotide—TACR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0161	0.021	CbGpPWpGaD
Vapreotide—TACR1—digestive system—acquired immunodeficiency syndrome	0.016	0.069	CbGeAlD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0159	0.0207	CbGpPWpGaD
Vapreotide—TACR1—blood—acquired immunodeficiency syndrome	0.0152	0.0657	CbGeAlD
Vapreotide—TACR1—spinal cord—acquired immunodeficiency syndrome	0.0147	0.0633	CbGeAlD
Vapreotide—SSTR2—brain—acquired immunodeficiency syndrome	0.0142	0.0613	CbGeAlD
Vapreotide—TACR1—lung—acquired immunodeficiency syndrome	0.0134	0.0576	CbGeAlD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0125	0.0163	CbGpPWpGaD
Vapreotide—SSTR5—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0124	0.0161	CbGpPWpGaD
Vapreotide—TACR1—nervous system—acquired immunodeficiency syndrome	0.0124	0.0533	CbGeAlD
Vapreotide—TACR1—central nervous system—acquired immunodeficiency syndrome	0.0119	0.0513	CbGeAlD
Vapreotide—SSTR5—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0116	0.0151	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0115	0.015	CbGpPWpGaD
Vapreotide—SSTR2—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0114	0.0149	CbGpPWpGaD
Vapreotide—SSTR2—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0107	0.014	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0106	0.0139	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0104	0.0136	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00961	0.0125	CbGpPWpGaD
Vapreotide—TACR1—brain—acquired immunodeficiency syndrome	0.00945	0.0408	CbGeAlD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00942	0.0123	CbGpPWpGaD
Vapreotide—TACR1—lymph node—acquired immunodeficiency syndrome	0.00913	0.0394	CbGeAlD
Vapreotide—TACR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00899	0.0117	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00878	0.0114	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00869	0.0113	CbGpPWpGaD
Vapreotide—TACR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00845	0.011	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00838	0.0109	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0081	0.0106	CbGpPWpGaD
Vapreotide—SSTR5—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00797	0.0104	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00757	0.00985	CbGpPWpGaD
Vapreotide—SSTR2—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00736	0.00958	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00699	0.0091	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00684	0.00891	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00645	0.00839	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00644	0.00838	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00638	0.00831	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00632	0.00823	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.00624	0.00812	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.00619	0.00806	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00594	0.00773	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00583	0.00759	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00582	0.00758	CbGpPWpGaD
Vapreotide—TACR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00579	0.00754	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00547	0.00712	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00547	0.00712	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00537	0.00699	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00532	0.00693	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00508	0.00661	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00505	0.00657	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00505	0.00657	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00491	0.00639	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00491	0.00639	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00481	0.00626	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00468	0.00609	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00462	0.00601	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00462	0.00601	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00459	0.00598	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00456	0.00593	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00453	0.0059	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00451	0.00587	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.00448	0.00583	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00444	0.00578	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00432	0.00562	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.00429	0.00559	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00428	0.00558	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00426	0.00555	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00426	0.00555	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00423	0.00551	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.0042	0.00547	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00416	0.00542	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00416	0.00541	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00398	0.00519	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00398	0.00518	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00398	0.00518	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00395	0.00515	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.0039	0.00508	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00387	0.00503	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00384	0.005	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00375	0.00488	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00367	0.00478	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00367	0.00478	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.0036	0.00469	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.00353	0.00459	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00351	0.00457	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.0035	0.00455	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00346	0.00451	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00339	0.00441	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00339	0.00441	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00329	0.00428	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00327	0.00426	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00324	0.00422	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00316	0.00412	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00314	0.00408	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00303	0.00395	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00302	0.00394	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00297	0.00387	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00294	0.00382	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00292	0.0038	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00284	0.00369	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00279	0.00364	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00279	0.00364	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00279	0.00364	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00274	0.00357	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00273	0.00355	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00272	0.00355	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00271	0.00353	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00267	0.00347	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00267	0.00347	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00266	0.00347	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.00259	0.00338	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00258	0.00336	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00258	0.00336	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00258	0.00335	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00252	0.00328	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00252	0.00327	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00247	0.00321	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00246	0.0032	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00239	0.00311	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00232	0.00302	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.0023	0.003	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00228	0.00297	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00216	0.00281	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00213	0.00277	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00203	0.00264	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00203	0.00264	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00203	0.00264	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00198	0.00258	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00196	0.00255	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00193	0.00252	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00192	0.00249	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00183	0.00238	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00179	0.00234	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00177	0.0023	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.00171	0.00222	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00169	0.0022	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00168	0.00219	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	0.00168	0.00219	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00161	0.0021	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00161	0.0021	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00158	0.00206	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00158	0.00206	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00156	0.00203	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00155	0.00202	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00154	0.00201	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00153	0.00199	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00149	0.00194	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00149	0.00194	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00146	0.0019	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00146	0.0019	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00146	0.0019	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00143	0.00187	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00143	0.00187	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00141	0.00183	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00139	0.00181	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.00138	0.00179	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	0.00135	0.00176	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00135	0.00175	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.00134	0.00175	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00132	0.00172	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00132	0.00172	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00123	0.0016	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00122	0.00159	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.0012	0.00156	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00118	0.00154	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00117	0.00153	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00117	0.00153	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00115	0.00149	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00115	0.00149	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00111	0.00144	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00111	0.00144	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00109	0.00142	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00109	0.00142	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.00108	0.00141	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00108	0.00141	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00107	0.0014	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00106	0.00138	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00104	0.00136	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00104	0.00136	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00101	0.00131	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000999	0.0013	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000997	0.0013	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000992	0.00129	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000983	0.00128	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00092	0.0012	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000907	0.00118	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000901	0.00117	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000873	0.00114	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00086	0.00112	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000847	0.0011	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000847	0.0011	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000838	0.00109	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000832	0.00108	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000793	0.00103	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000787	0.00102	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000782	0.00102	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000782	0.00102	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000781	0.00102	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000724	0.000943	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000714	0.00093	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000655	0.000852	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000645	0.000839	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000635	0.000827	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000625	0.000814	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000616	0.000801	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000616	0.000801	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000595	0.000774	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000586	0.000763	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000581	0.000756	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000577	0.000751	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000568	0.000739	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000536	0.000698	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000524	0.000682	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000468	0.00061	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000461	0.000601	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000454	0.000592	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000422	0.000549	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000413	0.000537	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000336	0.000437	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000334	0.000435	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.00031	0.000403	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000308	0.000401	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000244	0.000317	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000243	0.000316	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000197	0.000257	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000182	0.000237	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000143	0.000187	CbGpPWpGaD
